35.65
Schlusskurs vom Vortag:
$35.59
Offen:
$35.785
24-Stunden-Volumen:
2.34M
Relative Volume:
0.60
Marktkapitalisierung:
$15.02B
Einnahmen:
$2.26B
Nettoeinkommen (Verlust:
$1.09B
KGV:
15.21
EPS:
2.3431
Netto-Cashflow:
$2.70B
1W Leistung:
-1.63%
1M Leistung:
+2.27%
6M Leistung:
+17.66%
1J Leistung:
+26.69%
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RPRX
Royalty Pharma Plc
|
35.65 | 15.27B | 2.26B | 1.09B | 2.70B | 2.3431 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
2024-06-03 | Herabstufung | UBS | Buy → Neutral |
2022-06-14 | Fortgesetzt | UBS | Buy |
2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
2022-04-27 | Eingeleitet | Goldman | Buy |
2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
2021-07-30 | Eingeleitet | Tigress Financial | Buy |
2020-11-09 | Hochstufung | UBS | Neutral → Buy |
2020-07-14 | Eingeleitet | Evercore ISI | In-line |
2020-07-13 | Eingeleitet | BofA Securities | Buy |
2020-07-13 | Eingeleitet | Citigroup | Neutral |
2020-07-13 | Eingeleitet | Cowen | Outperform |
2020-07-13 | Eingeleitet | Goldman | Neutral |
2020-07-13 | Eingeleitet | JP Morgan | Neutral |
2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
2020-07-13 | Eingeleitet | SunTrust | Buy |
2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider
What drives Royalty Pharma plc stock priceFree Technical Analysis Support - jammulinksnews.com
What analysts say about Royalty Pharma plc stockOver 200% growth - jammulinksnews.com
C WorldWide Group Holding A S Acquires New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Los Angeles Capital Management LLC Grows Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc Stock Analysis and ForecastConsistent triple returns - Autocar Professional
Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat
Is Royalty Pharma plc a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
Edgestream Partners L.P. Invests $659,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Cullen Frost Bankers Inc. Has $7.72 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest
Royalty Pharma PLC Announces Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail
Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com
Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider
Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com South Africa
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times
Royalty Pharma adds two independent directors to board - Investing.com
Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative
Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan
Strata Wealth Advisors LLC Invests $387,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Cerity Partners LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Has $45.53 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Royalty Pharma Q2 2025 Earnings Call: Key Details for August 6 Pre-Market Release - Stock Titan
Why Royalty Pharma plc stock attracts strong analyst attentionDaily Swing Candidates - Newser
How Royalty Pharma plc stock performs during market volatilityMarket Timing Advice - beatles.ru
What makes Royalty Pharma plc stock price move sharplyFree Trading Group - Newser
M&T Bank Corp Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Fiera Capital Announces the Termination of imaxx Canadian Fixed Pay Fund and of imaxx Short Term Bond Fund - The Globe and Mail
Bank of New York Mellon Corp Has $45.53 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Rehmann Capital Advisory Group Purchases Shares of 17,649 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
D.A. Davidson & CO. Trims Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighTime to Buy? - MarketBeat
Teacher Retirement System of Texas Sells 12,028 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 36.44 USD By Investing.com - Investing.com South Africa
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):